SVRA

Savara Inc. [SVRA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SVRA Stock Summary

Top 10 Correlated Stocks

SVRA

In the News

SVRA Financial details

Company Rating
-
Market Cap
700.41M
Income
-52.38M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-14.85
Forward P/E
-
PEG
-5.44
P/S
-
P/B
4.8
P/C
-
P/FCF
-13.05
Quick Ratio
18.88
Current Ratio
18.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.32
EPS next Y
-
EPS next Q
-
EPS this Y
32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-10.5%
-
-
-
-
SMA20
-16.67%
SMA50
-16.67%
SMA100
-16.67%
Inst Own
-
Inst Trans
-
ROA
-26%
ROE
-43%
ROC
-0.31%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.69-5.7
52W High
+6.63%
52W Low
+433.14%
RSI
46
Rel Volume
0.83
Avg Volume
791.03K
Volume
656.98K
Perf Week
-0.35%
Perf Month
-3.77%
Perf Quarter
7.49%
Perf Half Y
-16.7%
-
-
-
-
Beta
0.697
-
-
Volatility
0.07%, 0.15%
Prev Close
0.21%
Price
5.3314
Change
-0.16%

Something similar

Top by Market Cap
CMC.DE
LLY.DE
V
JPM
FXAIX
Same Sector
2190.HK
GENE
PRCT
ALGS
ALR
Top Correlated Stocks
2014.TW
Similar Market Cap
FPI
IMMU.ST
0676.HK
FUTY
VAIAS.HE

Company Profile

Healthcare Biotechnology
  • Volume Average 791.03K
  • Market Capitalization 700.41M
  • Employee 37
  • CEO Mr. Matthew Pauls J.D., M.B.A.
  • Headquarters Austin,TX,US
  • IPO Date 2017-04-28
  • Website https://www.savarapharma.com

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.